LABU Holdings — Direxion Daily S&P Biotech Bull 3X Shares
All 154 reported holdings of Direxion Daily S&P Biotech Bull 3X Shares (LABU) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Dreyfus Government Cash Manage | 7.90% | $40.99M |
| Goldman Financial | 6.66% | $34.56M |
| Goldman Sachs Liq Es Fd A | 1.82% | $9.42M |
| Apellis Pharmaceuticals Inc | 1.53% | $7.95M |
| Revolution Medicines Inc | 1.35% | $7.03M |
| Travere Therapeutics Inc | 1.33% | $6.91M |
| Arrowhead Pharmaceuticals, Inc. | 1.18% | $6.14M |
| Twist Bioscience Corporation | 1.17% | $6.06M |
| Summit Therapeutics Inc. | 1.15% | $5.98M |
| Alkermes PLC | 1.14% | $5.89M |
| TG Therapeutics Inc | 1.13% | $5.85M |
| Madrigal Pharmaceuticals Inc | 1.12% | $5.82M |
| Beam Therapeutics Inc. | 1.09% | $5.65M |
| Apogee Therapeutics Inc. | 1.04% | $5.39M |
| Scholar Rock Holding Corp. | 1.01% | $5.24M |
| Praxis Precision Medicines, Inc. | 1.00% | $5.21M |
| Exelixis, Inc. | 1.00% | $5.17M |
| Mirum Pharmaceuticals Inc. | 0.99% | $5.15M |
| United Therapeutics Corporation | 0.98% | $5.09M |
| Natera Inc. | 0.98% | $5.09M |
| Celcuity Inc. | 0.98% | $5.09M |
| CRISPR Therapeutics AG | 0.98% | $5.09M |
| Krystal Biotech Inc | 0.96% | $4.99M |
| Protagonist Therapeutics Inc | 0.96% | $4.98M |
| Neurocrine Biosciences, Inc. | 0.95% | $4.93M |
| Incyte Corporation. | 0.94% | $4.89M |
| CG Oncology Inc. | 0.94% | $4.88M |
| Cytokinetics Inc | 0.94% | $4.88M |
| Nuvalent, Inc. | 0.94% | $4.87M |
| Ionis Pharmaceuticals, Inc. | 0.94% | $4.85M |
| Bridgebio Pharma Inc | 0.93% | $4.84M |
| Vaxcyte Inc | 0.93% | $4.83M |
| Kymera Therapeutics Inc | 0.93% | $4.83M |
| Biogen Inc | 0.93% | $4.82M |
| Cogent Biosciences Inc. | 0.93% | $4.82M |
| PTC Therapeutics, Inc. | 0.93% | $4.81M |
| Insmed Inc | 0.92% | $4.75M |
| Alnylam Pharmaceuticals, Inc. | 0.90% | $4.69M |
| Roivant Sciences Ltd | 0.90% | $4.68M |
| Halozyme Therapeutics Inc | 0.90% | $4.65M |
| Arcutis Biotherapeutics Inc. | 0.88% | $4.57M |
| Spyre Therapeutics Inc | 0.88% | $4.56M |
| Soleno Therapeutics Inc | 0.87% | $4.53M |
| AbbVie Inc. | 0.87% | $4.51M |
| Amgen Inc. | 0.86% | $4.45M |
| Regeneron Pharmaceuticals, Inc. | 0.85% | $4.43M |
| Ultragenyx Pharmaceutical, Inc. | 0.85% | $4.40M |
| Acadia Pharmaceuticals, Inc. | 0.85% | $4.39M |
| Rhythm Pharmaceuticals Inc | 0.85% | $4.39M |
| Gilead Sciences Inc. | 0.84% | $4.35M |
| Biomarin Pharmaceutical Inc. | 0.84% | $4.34M |
| Viking Therapeutics Inc. | 0.82% | $4.23M |
| Vertex Pharmaceuticals, Inc. | 0.81% | $4.21M |
| ImmunityBio Inc | 0.80% | $4.17M |
| Immunovant Inc | 0.77% | $3.99M |
| Moderna Inc | 0.77% | $3.98M |
| Vera Therapeutics Inc. | 0.75% | $3.90M |
| Immunome Inc | 0.74% | $3.86M |
| Disc Medicine Inc | 0.74% | $3.82M |
| Veracyte Inc | 0.71% | $3.69M |
| Sarepta Therapeutics Inc | 0.70% | $3.66M |
| Catalyst Pharmaceuticals Inc. | 0.70% | $3.66M |
| Biocryst Pharmaceuticals, Inc. | 0.67% | $3.49M |
| Dyne Therapeutics Inc. | 0.67% | $3.46M |
| Kodiak Sciences Inc | 0.64% | $3.35M |
| Recursion Pharmaceuticals, Inc. | 0.64% | $3.32M |
| GRAIL Inc | 0.63% | $3.25M |
| Arcus Biosciences Inc. | 0.61% | $3.16M |
| Agios Pharmaceuticals Inc | 0.60% | $3.10M |
| Denali Therapeutics Inc | 0.59% | $3.04M |
| Oruka Therapeutics Inc | 0.57% | $2.98M |
| Dianthus Therapeutics Inc | 0.57% | $2.95M |
| Intellia Therapeutics Inc | 0.56% | $2.90M |
| Erasca Inc | 0.56% | $2.89M |
| Adma Biologics, Inc. | 0.56% | $2.89M |
| Syndax Pharmaceuticals Inc. | 0.55% | $2.88M |
| Ardelyx Inc | 0.54% | $2.78M |
| IDEAYA Biosciences Inc. | 0.52% | $2.72M |
| Mineralys Therapeutics Inc. | 0.52% | $2.71M |
| Nurix Therapeutics Inc. | 0.52% | $2.69M |
| Tango Therapeutics Inc. | 0.47% | $2.44M |
| Celldex Therapeutics Inc. | 0.44% | $2.30M |
| Capricor Therapeutics, Inc. | 0.43% | $2.25M |
| Vericel Corporation | 0.43% | $2.22M |
| Inhibrx Biosciences Inc. | 0.42% | $2.19M |
| Monte Rosa Therapeutics Inc | 0.42% | $2.16M |
| Novavax Inc | 0.41% | $2.12M |
| Biohaven Ltd | 0.41% | $2.11M |
| Stoke Therapeutics Inc | 0.41% | $2.11M |
| Relay Therapeutics Inc | 0.40% | $2.10M |
| Taysha Gene Therapies Inc. | 0.40% | $2.06M |
| Viridian Therapeutics Inc | 0.40% | $2.06M |
| Olema Pharmaceuticals Inc. | 0.39% | $2.04M |
| Palvella Therapeutics Inc. | 0.39% | $2.02M |
| Uniqure N.V. | 0.37% | $1.94M |
| AnaptysBio Inc. | 0.37% | $1.93M |
| Corvus Pharmaceuticals Inc | 0.35% | $1.84M |
| Mannkind Corp. | 0.34% | $1.77M |
| Caredx Inc | 0.34% | $1.76M |
| Kalvista Pharmaceuticals, Inc. | 0.32% | $1.64M |
| Iovance Biotherapeutics Inc | 0.30% | $1.57M |
| VIR Biotechnology Inc | 0.28% | $1.48M |
| Geron Corp. | 0.28% | $1.46M |
| Precigen Inc | 0.28% | $1.43M |
| Sellas Life Sciences Group, Inc. | 0.26% | $1.33M |
| Tyra Biosciences Inc | 0.25% | $1.30M |
| Absci Corp. | 0.25% | $1.29M |
| Annexon Inc | 0.25% | $1.28M |
| Kura Oncology Inc. | 0.25% | $1.28M |
| Sana Biotechnology Inc | 0.24% | $1.25M |
| ArriVent BioPharma Inc. | 0.24% | $1.25M |
| ORIC Pharmaceuticals Inc. | 0.24% | $1.23M |
| Rigel Pharmaceuticals Inc. | 0.23% | $1.17M |
| Janux Therapeutics Inc | 0.23% | $1.17M |
| Cytomx Therapeutics Inc | 0.21% | $1.09M |
| Savara Inc | 0.21% | $1.07M |
| ARS Pharmaceuticals Inc | 0.20% | $1.05M |
| Zenas Biopharma, Inc. | 0.19% | $1.00M |
| Cullinan Therapeutics Inc | 0.19% | $976.00K |
| Xencor Inc | 0.19% | $970.51K |
| Ironwood Pharmaceuticals, Inc. | 0.19% | $961.77K |
| Sionna Therapeutics Inc. | 0.18% | $922.10K |
| Bicara Therapeutics Inc. | 0.17% | $882.69K |
| Hyperliquid Strategies, Inc. | 0.17% | $860.38K |
| Prime Medicine Inc | 0.16% | $822.56K |
| Vor Biopharma, Inc. | 0.15% | $778.95K |
| Emergent Biosolutions Inc | 0.15% | $754.73K |
| Regenxbio Inc. | 0.14% | $713.29K |
| Vanda Pharmaceuticals, Inc. | 0.14% | $705.39K |
| First Tracks Biotherapeutics, Inc. | 0.13% | $682.46K |
| 4d Molecular Therapeutics, Inc. | 0.13% | $681.63K |
| Altimmune Inc. | 0.12% | $647.20K |
| Allogene Therapeutics, Inc. | 0.12% | $647.30K |
| Verastem Inc | 0.12% | $641.31K |
| Prothena Corporation PLC | 0.12% | $634.05K |
| Lexeo Therapeutics Inc | 0.12% | $618.45K |
| Myriad Genetics Inc. | 0.12% | $598.23K |
| Arbutus Biopharma Corp. | 0.11% | $555.39K |
| Rocket Pharmaceuticals, Inc. | 0.10% | $528.93K |
| Ocugen, Inc. | 0.10% | $526.78K |
| Anavex Life Sciences Corp. | 0.10% | $516.79K |
| Akebia Therapeutics Inc. | 0.09% | $485.87K |
| Invivyd Inc | 0.09% | $461.54K |
| MiMedx Group Inc. | 0.09% | $447.17K |
| Perspective Therapeutics, Inc. | 0.08% | $389.60K |
| Compass Therapeutics Inc | 0.07% | $373.15K |
| Replimune Group Inc | 0.06% | $327.73K |
| Damora Therapeutics, Inc. | 0.03% | $140.41K |
| Dreyfus | 0.00% | $0 |
| Omniab, Inc. | 0.00% | $0 |
| Verve Therapeutics, Inc. (cvr) | 0.00% | $0 |
| Omniab, Inc. | 0.00% | $0 |
| Novob Dc Cvr | 0.00% | $0 |
| Inhibrx, Inc. Cvr | 0.00% | $0 |
LABU overview: performance, fees, allocation and SEC filings